When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cance ...

Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the ...

Japan’s MHLF approves Padcev with Keytruda for first-line treatment of radically unresectable urothelial carcinoma: Tokyo Wednesday, September 25, 2024, 11:00 Hrs [IST] Astellas ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...

AEMD READ THE FULL AEMD RESEARCH REPORT AEMD basket oncology trial, patient enrollment process We participated in a ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's ...